Market Intelligence
In a busy month for triple-digit percentage average price rises for generics in the UK, repaglinide led the pack in December.
The US ranibizumab market has seen more than its fair share of ups and downs, with the latest developments vastly reducing biosimilar penetration and allowing Lucentis to recapture around 90% of the market. Generics Bulletin looks at the reasons why.
Propranolol prices that were almost five times higher in November meant that the beta-blocker topped our table of UK price rises this month, as ciprofloxacin prices also continued to climb.
When it comes to predicting the future for generic GLP-1s, Sandoz CEO Richard Saynor believes that “everyone’s asking the wrong questions,” pointing to the importance of manufacturing capacity and ability to supply the, rather than the potential market size, as the key factor.
Thanks to a late surge in pricing in October, ciprofloxacin 500mg tablets had the fastest-rising generic price in the UK last month, according to the latest figures from WaveData.
Sandoz’s CEO used the firm’s latest results call to highlight “trade distortion” in the pencillins market as a result of US tariffs, urging European authorities to take action to reduce the region’s “geopolitical exposure” and safeguard the long-term sustainability of European-produced penicillins.
Building on increases seen in August, UK price rises continued to be seen across multiple presentations of olanzapine in September, according to the latest figures from WaveData.
A massive 1,115% average price increase was seen for indapamide 2.5mg tablets in the UK in August.
An executive order has given the go-ahead for US tariffs on Japan to be amended to “zero percent” for generics, just weeks after the EU revealed an effective exemption from its own US tariffs. Meanwhile, a separate order suggests that generics could enjoy broader global exemptions from tariffs.
In its latest savings report, the AAM calculates that using generics and biosimilars saved the US around $467bn in 2024, with more than $20bn of this figure coming from biosimilars.
High-strength ibuprofen tablets saw the largest average price increase of all UK generics in July, according to the latest figures from WaveData.
This article compiles all of the data from Generics Bulletin’s 2025 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.
In the third instalment of this year’s Generics Bulletin Top 50, we reveal which firms have entered the ranking for the first time.
In the second instalment of Generics Bulletin’s Top 50 ranking for 2025, we see plenty of movement among our mid-table collection of companies.
Two leading German generics and biosimilars giants were the big movers in our top ten ranking of off-patent industry leaders for 2025. We reveal the latest developments among the top players in the first instalment of this year’s Generics Bulletin Top 50.
Multiple strengths of sitagliptin saw average price increases that topped our rundown of UK generic pricing data in June.
As multiple molecules experienced triple-digit percentage price rises in May, pioglitazone once again led the way after already topping our table of price increases in April.
Diabetes medication pioglitazone topped the list of the fastest-rising UK generics prices in April, according to market researcher WaveData.
One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.
Trihexyphenidyl tablets in two different strengths led a raft of UK generic price rises in March, according to the latest figures from WaveData.